Derniers articles

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

AbstractBackground: The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients,...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Ann Oncol

An international tool to measure perceived stressors in intensive care units: the PS-ICU scale

AbstractBackground: The intensive care unit is increasingly recognized as a stressful environment for healthcare...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : Ann Intensive Care .

Feasibility of a prehabilitation programme dedicated to older patients with cancer before complex medical-surgical procedures: the PROADAPT pilot study protocol

AbstractBackground: Ageing is associated with an increased prevalence of comorbidities and sarcopenia as well as a...

Posté par : Dr. Sophie PAGET-BAILLY
Nom de la revue : BMJ Open

Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma

AbstractKeywords: RTQA; chemoradiotherapy; locally advanced; pancreatic adenocarcinoma; quality control; radiation...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Int J Radiat Oncol Biol Phys

Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma

AbstractPurpose: Baseline neutrophil count may predict overall survival (OS) in patients with locally advanced...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Int J Radiat Oncol Biol Phys

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. Large genomic analyses with prognostic assessments are...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

AbstractAims: The addition of docetaxel to cisplatin and 5-fluorouracil (DCF) has shown promising efficacy in...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Ther Adv Med Oncol

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

AbstractBackground: The IMMUNOBIL PRODIGE 57 trial is a non-comparative randomized phase II study assessing the...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

AbstractFluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

AbstractBackground: A prospective, pooled analysis of six randomised phase 3 trials was done to investigate...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

Feasibility of health‑related quality of life (HRQoL) assessment for cancer patients using electronic patient‑reported outcome (ePRO) in daily clinical practice

AbstractIntroduction - Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical...

Posté par : , Mr. Antoine FALCOZ, Mme. Joëlle FRITZSCH, , , Dr. Sophie PAGET-BAILLY
Nom de la revue : Quality of Life Research

How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial

In their recent article in Journal of Clinical Oncology regarding the InterAAct phase II trial in advanced...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol

11 Novembre, 2020

Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients

AbstractBackground: Randomized controlled trials (RCTs) represent the best evidence in oncology research....

Posté par : Mr. Antoine FALCOZ, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY
Nom de la revue : Neurooncol Pract

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

AbstractBackground: Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : J Immunother Cancer

Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. We conducted a prospective cohort to describe the prevalence,...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma

AbstractIn metastatic pancreatic adenocarcinoma, a high neutrophil-to-lymphocyte ratio (NLR) at diagnosis is a marker of...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clin Res Hepatol Gastroenterol

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial

AbstractImportance: In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage II...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : JAMA Netw Open .

Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials

AbstractBackground: While open-label randomized controlled trials (RCT) are common in oncology, some concerns have...

Posté par :
Nom de la revue : Cancer Med

FOLFIRINOX De‐Escalation in Advanced Pancreatic Cancer: A Multicenter Real‐Life Study

AbstractBackground: Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Oncologist

Anti-Telomerase CD4 + Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials

AbstractDocetaxel, cisplatin and 5-fluorouracil (DCF) chemotherapy regimen is highly effective in advanced anal squamous...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Int J Mol Sci